413 related articles for article (PubMed ID: 25755107)
21. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
[TBL] [Abstract][Full Text] [Related]
22. One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients.
Badalamenti G; Incorvaia L; Messina C; Musso E; Casarin A; Ricciardi MR; De Luca I; Bazan V; Russo A
Support Care Cancer; 2019 Sep; 27(9):3593-3597. PubMed ID: 30762142
[TBL] [Abstract][Full Text] [Related]
23. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
Rapoport B; van Eeden R; Smit T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202
[TBL] [Abstract][Full Text] [Related]
24. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
25. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
26. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
27. Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
Aapro M; Jordan K; Scotté F; Celio L; Karthaus M; Roeland E
Curr Cancer Drug Targets; 2022; 22(10):806-824. PubMed ID: 35570542
[TBL] [Abstract][Full Text] [Related]
28. An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
Fabi A; Malaguti P
Expert Opin Pharmacother; 2013 Apr; 14(5):629-41. PubMed ID: 23414148
[TBL] [Abstract][Full Text] [Related]
29. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Navari RM
Drug Des Devel Ther; 2015; 9():155-61. PubMed ID: 25552904
[TBL] [Abstract][Full Text] [Related]
30. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
Celio L; Agustoni F; Testa I; Dotti K; de Braud F
Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
[TBL] [Abstract][Full Text] [Related]
31. Advances in the Management of Chemotherapy-Induced Nausea and Vomiting: New Data From Recent and Ongoing Trials.
Roeland E; Aapro MS; Schwartzberg LS
Clin Adv Hematol Oncol; 2015 Oct; 13(10 Suppl 10):1-14. PubMed ID: 26859507
[TBL] [Abstract][Full Text] [Related]
32. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
Bosnjak SM; Dimitrijevic J; Djordjevic F
Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
34. Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
Navari RM
Expert Opin Pharmacother; 2009 Mar; 10(4):629-44. PubMed ID: 19284365
[TBL] [Abstract][Full Text] [Related]
35. Fixed Combination Antiemetic: A Literature Review on Prevention of Chemotherapy-Induced Nausea and Vomiting Using Netupitant/Palonosetron.
Clark-Snow RA; Vidall C; Börjeson S; Jahn P
Clin J Oncol Nurs; 2018 Apr; 22(2):E52-E63. PubMed ID: 29547597
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting.
Ahmed H; Hammad AM; Abushouk AI; Zidan M; Salem M; Negida A; Abdel-Daim MM
Curr Probl Cancer; 2018; 42(2):241-255. PubMed ID: 29310827
[TBL] [Abstract][Full Text] [Related]
37. New options and controversies in the management of chemotherapy-induced nausea and vomiting.
Koth SM; Kolesar J
Am J Health Syst Pharm; 2017 Jun; 74(11):812-819. PubMed ID: 28396308
[TBL] [Abstract][Full Text] [Related]
38. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
39. Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.
Lorusso V; Giampaglia M; Petrucelli L; Saracino V; Perrone T; Gnoni A
Support Care Cancer; 2012 Dec; 20(12):3241-6. PubMed ID: 22534864
[TBL] [Abstract][Full Text] [Related]
40. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ
Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]